Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
XTL Biopharmaceuticals Ltd ADR (XTLB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/18/2025: XTLB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 8.81% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.22M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) - | Beta 0.99 | 52 Weeks Range 0.86 - 3.05 | Updated Date 06/29/2025 |
52 Weeks Range 0.86 - 3.05 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -227.72% | Operating Margin (TTM) -200.49% |
Management Effectiveness
Return on Assets (TTM) -24.74% | Return on Equity (TTM) -26.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9117987 | Price to Sales(TTM) 22.67 |
Enterprise Value 9117987 | Price to Sales(TTM) 22.67 | ||
Enterprise Value to Revenue 20.22 | Enterprise Value to EBITDA 16.88 | Shares Outstanding 8813850 | Shares Floating 451886180 |
Shares Outstanding 8813850 | Shares Floating 451886180 | ||
Percent Insiders 41.29 | Percent Institutions 2.92 |
About XTL Biopharmaceuticals Ltd ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2005-09-01 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 10 | Website https://www.xtlbio.com |
Full time employees 10 | Website https://www.xtlbio.com | ||
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.